Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF‐1 suppression to octreotide LAR in healthy volunteers

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2125|80|3|460-472

ISSN： 0306-5251

Source： BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol.80, Iss.3, 2015-09, pp. : 460-472

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

From somatostatin to octreotide LAR: evolution of a somatostatin analogue

By Anthony Lowell   Freda Pamela U.  

Current Medical Research and Opinion, Vol. 25, Iss. 12, 2009-12 ,pp. : 2989-2999

Informa Healthcare

Access to resources Recommend Favorite

Long-Term Efficacy of S-1 Chemotherapy plus Administration of Octreotide for a Patient with Metastatic Neuroendocrine Tumor (Gastrinoma)

By  

Case Reports in Oncology, Vol. 10, Iss. 2, 2017-05 ,pp. : 420-427

Karger

Access to resources Recommend Favorite

Scintigraphic Imaging of Sarcomatous Tumors with [111In-DTPA-Phe-1]-Octreotide

By  

Oncology, Vol. 58, Iss. 1, 2000-01 ,pp. : 18-24

Karger

Access to resources Recommend Favorite

Effects of Octreotide Pretreatment in Experimental Acute Pancreatitis

By  

Pancreatology, Vol. 3, Iss. 2, 2003-05 ,pp. : 164-168

Karger

Access to resources Recommend Favorite

Treatment of Chinese acromegaly with a combination of bromocriptine and octreotide

By  

INTERNAL MEDICINE JOURNAL, Vol. 30, Iss. 4, 2000-08 ,pp. : 457-461

John Wiley & Sons Inc

Access to resources Recommend Favorite